Dalal's tenure with Chiron was a good one. It's Chiron's blood testing business that has kept it's earnings positive these last several years.
>>FREMONT, Calif., April 9 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH - News) announced today that Rajen Dalal, President and Chief Executive Officer of Guava Technologies, Inc., has joined Ciphergen's Board of Directors. Rajen joined Guava, a biotechnology company based on mammalian cell profiling and analysis, in the spring of 2002 after a decade long tenure at Chiron Corporation where he was president of its Blood Testing division. Under his leadership, Blood Testing became the company's fastest growing and most productive division, with revenues exceeding $300 million. While at Chiron, Rajen led post-merger integration initiatives, corporate-level joint ventures, business collaborations, and technology licensing agreements in drug discovery, biopharmaceuticals, vaccines and gene therapy. Prior to joining Chiron, Rajen was a leader of McKinsey & Company's pharmaceuticals and technology management groups. Rajen received his bachelor's degree in chemistry from St. Xavier's College, the University of Bombay; his master's in biochemical engineering from the Massachusetts Institute of Technology; and his MBA from the University of Chicago. He is a member of the U.S. Department of Health and Human Services' Advisory Committee on Blood Safety and Availability; a board member for Sagres Discovery, a cancer biotechnology company; an advisory board member of Outward Bound West; and a corporation member of the Bermuda Biological Station for Research.
William Rich, President and CEO of Ciphergen, stated, "Rajen's extensive experience in successfully building a major diagnostics business and now leading a pioneering effort as CEO of an early stage biotechnology company, brings important and relevant perspectives to our board."
Rajen Dalal added, "I'm delighted to be joining Ciphergen's Board of Directors. Biotechnology companies are developing powerful new diagnostic tools that are changing drug discovery, clinical trials and patient management. One of the more promising applications of the ProteinChip technology is the discovery of protein-based predictive diagnostics based on biomarkers and patterns of biomarkers."<<
snip, emphasis mine
Cheers, Tuck |
